Anna R. Petrosyan
Research Subjects
Research Interests
Anna R. Petrosyan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Anahit Z. Aznauryan
Yerevan State Medical University after M. Heratsi
2 shared publications - Artyom I. Trofimenko
Kuban State Medical University
2 shared publications - Ashot Avagimyan
Department of Internal Diseases Propedeutics, Yerevan State Medical University, Yerevan 0025, Armenia
2 shared publications - Evgenii E. Lysov
Kuban State Medical University
2 shared publications - Farida M. Khamidova
Samarkand State Medical University, Samarkand, Uzbekistan
2 shared publications - Gayane L. Mkrtchyan
Yerevan State Medical University after M. Heratsi
2 shared publications
Latest Publications
- Open Access
- 26 February 2025
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- Vol. 10 (1) , 101-109
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are now uncovering new possibilities in the field of internal medicine owing to their diverse protective effects. In the second part of the literature review, we explore potential applications of SGLT2i in hepatology, neurology, ophthalmology, and oncology, mechanisms of action of such drugs as dapagliflozin, empagliflozin, canagliflozin, etc, and their effect on different organs and systems.
- 26 February 2025
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- Vol. 10 (1) , 101-109
Open AccessProtective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 2)
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are now uncovering new possibilities in the field of internal medicine owing to their diverse protective effects. In the second part of the literature review, we explore potential applications of SGLT2i in hepatology, neurology, ophthalmology, and oncology, mechanisms of action of such drugs as dapagliflozin, empagliflozin, canagliflozin, etc, and their effect on different organs and systems.
- Open Access
- 15 November 2024
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- No. 4,p. 126-135
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a revolutionary class of drugs with far-reaching protective effects in multiple organs. The protective potential of SGLT2i is much broader than that of the classical concept of glucose control and consists of an entire conglomerate of associated pleiotropic effects. This study aims to provide a descriptive review of the pleiotropic therapeutic potential of SGLT2i. The first part of the literature review examined the use of SGLT2i in cardiology and nephrology. The use of SGLT2i represents an innovative approach to improving patients’ quality of life and course of heart failure and chronic kidney disease, regardless of left ventricular ejection fraction and type 2 diabetes.
- 15 November 2024
- Published by Scientific Research Institute - Ochapovsky Regional Clinical Hospital No 1 in Innovative Medicine of Kuban
- No. 4,p. 126-135
Open AccessProtective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1)
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a revolutionary class of drugs with far-reaching protective effects in multiple organs. The protective potential of SGLT2i is much broader than that of the classical concept of glucose control and consists of an entire conglomerate of associated pleiotropic effects. This study aims to provide a descriptive review of the pleiotropic therapeutic potential of SGLT2i. The first part of the literature review examined the use of SGLT2i in cardiology and nephrology. The use of SGLT2i represents an innovative approach to improving patients’ quality of life and course of heart failure and chronic kidney disease, regardless of left ventricular ejection fraction and type 2 diabetes.